Join our email list for exclusive offers! OFF! 👏

S23 Powder | 2 Grams

 Selling fast! Get yours today  Same-day shipping available

$67.99

In stock

Description

Research-Grade SARM Reference Material

S23 Powder — 2 Grams

S23, also designated S-23, is a non-steroidal selective androgen receptor modulator (SARM) of the aryl-propionamide class, developed in academic research at the University of Tennessee. This listing is a research-grade reference compound supplied in powder form for in vitro and laboratory investigation. Identity and purity are third-party verified and documented by a downloadable Certificate of Analysis.

  • 99.8% purity (HPLC)
  • Third-party verified
  • 2,050 mg net
  • Public COA
  • UV-resistant foil pouch
Technical Reference

Specifications & Documentation

Compound
S23 (S-23)
IUPAC Name
(2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
CAS Number
1010396-29-8
Molecular Formula
C₁₈H₁₃ClF₄N₂O₃
Molar Mass
416.76 g/mol
Compound Class
Selective Androgen Receptor Modulator (SARM) · Aryl-propionamide
WADA Classification
Prohibited — Class S1.2 (Other Anabolic Agents)
Form
Crystalline powder
Net Quantity
2,050 mg per pouch
Verified Purity
99.8% by HPLC (current COA)
Why Verification Matters

Quality & Analytical Transparency

Independent analysis has repeatedly found that materials sold online as SARMs are frequently mislabeled or adulterated. A 2017 JAMA investigation that chemically analyzed products marketed as SARMs found that only a minority accurately matched their labeled contents, and a substantial share contained unapproved or entirely different substances.[5] Third-party testing is the control that distinguishes a documented reference compound from an unverified one.

99.8%HPLC Purity
HPLCPurity Method
MSIdentity Confirmation
GLPTesting Standard
Scientific Background

Research Context

S23 was developed and characterized by the University of Tennessee research group responsible for several early aryl-propionamide SARMs.[4] Its preclinical characterization in rats evaluated high-affinity androgen receptor binding, tissue selectivity, and its potential as a component of hormonal male contraception, including the reversibility of its effects on spermatogenesis.[1] Later rat studies examined it in models of glucocorticoid- and hypogonadism-induced muscle atrophy[2] and of sexual motivation in ovariectomized female rats.[3] S23 has not been evaluated in published human clinical trials, and its safety profile in humans is unknown.

This material is supplied strictly as a reference compound to support such laboratory investigation. It is not a therapeutic product, dietary supplement, or sports supplement, and no clinical or performance outcomes are claimed or implied for any individual.

Regulatory Status

Compliance & Legal Status

S23 is an investigational compound that has not been approved by the U.S. Food and Drug Administration for human use. It is not a dietary supplement, and marketing it for human ingestion is unlawful. It is supplied exclusively for laboratory research purposes.

FDA StatusNot approved for human use; not a dietary or sports supplement.
WADA StatusProhibited at all times — Class S1.2, Other Anabolic Agents.[6]
Intended UseLaboratory / in vitro research reference material only.
Not ForHuman or animal consumption, diagnosis, treatment, or performance use.
Citations

Scientific References

  1. Jones A, Chen J, Hwang DJ, Miller DD, Dalton JT. Preclinical characterization of a (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro, 4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide: a selective androgen receptor modulator for hormonal male contraception. Endocrinology. 2009;150(1):385–395.
  2. Jones A, Hwang DJ, Narayanan R, Miller DD, Dalton JT. Effects of a novel selective androgen receptor modulator on dexamethasone-induced and hypogonadism-induced muscle atrophy. Endocrinology. 2010;151(8):3706–3719.
  3. Jones A, Hwang DJ, Duke CB 3rd, et al. Nonsteroidal selective androgen receptor modulators enhance female sexual motivation. J Pharmacol Exp Ther. 2010;334(2):439–448.
  4. Narayanan R, Mohler ML, Bohl CE, Miller DD, Dalton JT. Selective androgen receptor modulators in preclinical and clinical development. Nucl Recept Signal. 2008;6:e010.
  5. Van Wagoner RM, Eichner A, Bhasin S, Deuster PA, Eichner D. Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet. JAMA. 2017;318(20):2004–2010.
  6. World Anti-Doping Agency. The Prohibited List, Section S1.2: Other Anabolic Agents. WADA.org.

Research Disclaimer

For laboratory research use only. This preparation is not approved by the FDA for human use. S23 is not a dietary or sports supplement and is not intended for human or animal consumption.

All products on this website are intended exclusively for research and development purposes. The statements herein have not been evaluated by the U.S. Food and Drug Administration. Neither the statements nor the products are intended to diagnose, treat, cure, or prevent any disease. Sports Technology Labs are chemical suppliers, not medical practitioners; our expertise is sourcing and quality control.

Additional information

Weight 3.0 oz
Dimensions 3 × .3 × 4 in

Related Products